Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a commonly encountered disease entity following chemotherapy for cancer treatment. Although only duloxetine is recommended by the American Society of Clinical Oncology (ASCO) for the treatment of CIPN in 2014, the evidence of the clinical outcome for new pharmaceutic therapies and non-pharmaceutic treatments has not been clearly determined.
www.painphysicianjournal.com therapeutic questions in the 2011 American Academy of Neurology (AAN) Clinical Practice Guideline Process Manual (16, 17) . We chose to use the AAN Clinical Practice Guideline Process Manual for this review because it formed the basis of 45 evidence-based reviews published by the AAN and made available on the Agency for Healthcare Research and Quality's National Guideline Clearinghouse (www.guideline.gov), a public resource for evidence-based clinical practice guidelines (16) (17) (18) . It has been widely used by many authors (19) (20) (21) (22) .
Criteria for Considering Studies for this Review

Types of Studies
RCTs and prospective non-randomized, case-control, cohort, and cross-over studies, and retrospective studies published in English from January, 1990 to September, 2017 were included. Case reports, case series, abstracts, book chapter, and review articles, letters to the editor, and newspaper articles were excluded. Animal studies and studies of children were also excluded.
Types of Participants
Patients of interest were adults with CIPN of at least 18 years of age.
Types of Interventions
Studies evaluating any treatment modality, including pharmacologic and non-pharmacologic modalities, were included.
Types of Outcome Measures
Outcome measures are variable in all selected studies so that the uses of specific outcome measures were not inclusion criteria. Here we mainly focus on pain relief and the change in severity of neuropathic symptoms as the primary outcome parameter.
Literature Search
All of the available trials or studies in any language from any country describing appropriate management of CIPN with outcome evaluations were considered for inclusion. We searched Pubmed, Scopus, the Cochrane Library, and ClinicalTrials.gov for studies published from January 1990 through September 2017.
The search strategy was designed to identify studies of the treatment of CIPN. The search terms included: "chemotherapy," "peripheral neuropathy," "neurooften distributed in a "stocking and glove" manner, causing symptoms such as pain, allodynia, loss of sensation, paresthesia, numbness, tingling, and gait disturbance (2, 3) . CIPN can cause significant loss of functional abilities and negatively affect quality of life, which can lead to dose reductions, discontinuation of treatment, and ultimately affect overall survival (2) . CIPN has dose limiting side effect that likely will increase in prevalence as new cancer therapies extend patient survival times. One study established the prevalence of CIPN at 68.1% in the first month after chemotherapy, 60.0% at 3 months, and 30.0% at 6 months or more (1) . Some chemotherapy drugs were associated with even higher prevalence and duration of CIPN. For instance, approximately 80% of patients who received taxanes and oxaliplatin therapy continue to suffer from CIPN even 6 months or 2 years after chemotherapy (4) (5) (6) .
At present, no sufficient treatment options are available for CIPN and its exact pathophysiology is not clear. CIPN is most commonly considered as neuropathic pain due to axonopathy by dying back axonal degeneration (7) . However, most of the pharmacologic treatments for neuropathic pain including tricyclic antidepressants, and anticonvulsants, are minimally effective in CIPN or have unacceptable side effects (8) (9) (10) (11) . Therefore, the mechanisms underlying CIPN may differ from those involved in typical neuropathic pain conditions.
To date only duloxetine is recommended by the American Society of Clinical Oncology (ASCO) for the treatment of CIPN, on the bases of a modest positive result in 1 randomized control trial (RCT) (12) . In addition, several systemic reviews (12) (13) (14) (15) evaluating strategies for the prevention and treatment of CIPN have been recently published; however these reviews focus only on pharmacologic treatments of CIPN and were mainly limited to RCTs. Here we performed the evaluation of all selected studies, not only of pharmacologic treatments, but also of non-pharmacologic treatment modalities. The goals of this systematic review were to 1) provide a comprehensive systematic review for all available treatments for CIPN; 2) evaluate the strengths and weaknesses of each study; and 3) summarize the level of evidence and provide evidence-based recommendations.
Methods
The methodology used in this systematic review followed the procedures for systematic reviews of Treatment of Chemotherapy Induced Peripheral Neuropathy pathic pain," "treatment," and "cancer." Different combinations of the search terms were made by using the Boolean operators "AND," "OR," and "NOT."
Data Extraction
Two review authors working independently, in a non-blinded standardized manner, searched for relevant literature, and extracted the data from the included studies. Disagreements were resolved by discussion between the 2 authors; if no agreement could be reached, another resolved the dispute.
Analysis of Evidence
The quality of the included studies' evidence was analyzed using the methods described in the 2011 AAN Clinical Practice Guideline Process Manual (16, 17) . Studies were first classified on the basis of the strength of the evidence they presented into 4 levels ranging from the strongest, Class I, to the weakest, Class IV ( Table  1 ). The level of confidence in the evidence was determined using 4 levels of confidence, as described in the 2011 AAN Clinical Practice Guideline Process Manual ( Table 2 ). Level of confidence in evidence is initially Table 1 . Rating scheme for the strength of evidence for therapeutic questions.
Class I
Randomized, controlled clinical trial (RCT) in a representation population Masked or objective outcome assessment Relevant baseline characteristics are presented and substantially equivalent between treatment groups, or there is appropriate statistical adjustment for differences Also required: Concealed allocation No more than 2 primary outcomes specified Exclusion/inclusion criteria clearly defined Adequate accounting for dropouts (with at least 80 percent of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias For noninferiority or equivalence trials claiming to prove efficacy for 1 or both drugs, the following are also required * The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose, and dosage adjustments are similar to those previously shown to be effective) The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment The interpretation of the study results is based on a peer-protocol analysis that accounts for dropouts or crossovers. For crossover trials, both period and carryover effects examined and statistical adjustments performed, if appropriate Class II An RCT that lacks 1 or 2 criteria a-e (see Class I) or a cohort study meeting criteria b-e (see Class I) Randomized, crossover trial missing 1 of the following 2 criteria: Period and carryover effects described Baseline characteristics of treatment order groups presented All relevant baseline characteristics are presented and substantially equivalent among treatment groups, or there is appropriate statistical adjustment for differences Masked or objective outcome assessment Class III Controlled studies (including studies with external controls such as well-defined natural history controls) Crossover trial missing both of the following 2 criteria: Period and carryover effects Baseline characteristics presented A description of major confounding differences between treatment groups that could affect outcome ** Outcome assessment masked, objective, or performed by someone who is not a member of the treatment team Class IV Did not include patients with the disease Did not include patients receiving different interventions Undefined or unaccepted interventions or outcome measures No measures of effectiveness or statistical precision presented or calculable *Numbers 1-3 in Class I are required for Class II in equivalence trials. If any 1 of the 3 is missing, the class is automatically downgraded to Class III **Objective outcome measurement: An outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data) .
www.painphysicianjournal.com anchored to class of evidence; then considering various factors that can downgrade or upgrade confidence in evidence, which was described previously (16, 17) . The strength of the recommendations for use of the therapeutic modalities was determined on basis of the level of confidence in the evidence. Recommendation strength was stratified into 4 levels: A, clinicians must or must not offer the treatment; B, clinicians should or should not offer the treatment; C, clinicians may or may not offer the treatment; and U, no recommendation (Table 3) (16, 17) . Other factors that affected the recommendation strength included: the generalizability of the study, the clinical importance of the treatment's effect, the risk of harm weighed against the benefit of the treatment, the treatment availability and cost, and the alternative interventions.
Results
Search Results
A total of 1,288 relevant studies were identified by the literature search. Of these, 117 studies were examined in detail and a total of 35 studies ultimately met all inclusion criteria (3, (8) (9) (10) (11) . The included studies described total 26 treatment options for CIPN, including pharmacological therapy, light therapy, scrambler therapy, magnetic field therapy, acupuncture, dietary therapy and long-wave diathermy therapy, etc. Among included studies, 7 successful RCTs, 6 failed RCTs, 18 prospective studies, and 4 retrospective studies were identified (Fig. 1) . Table 4 described the results of each study reviewed. The strengths and weaknesses of each study were evaluated and quality assessment is summarized in Table 5 . On the basis of the AAN criteria, the level of confidence in the evidence was determined for each treatment options. But there are various factors that can downgrade (e.g., power) or upgrade confidence in evidence (16, 17) . Based on the strengths and weaknesses for each study, the level of confidence in evidence for each treatment option was summarized in Table 6 . Among 7 successful RCTs, duloxetine had Class II level of strength of evidence and photobiomodulation had Class I, but downgraded to Class II due to relative small sample size. The remaining 5 studies were identified as 2 Class IV and 3 Class II initially, then downgraded to very low level of confidence in evidence due to poor design quality. In 6 failed RCTs, 2 Class II large sample size studies with treatment of lamotrigine, and topical 2% amitriptylin/ 4% ketamine showed negative outcome. Other studies presented with poor design quality with Class IV evidence level.
Quality Assessment
Recommendations
The strength of the recommendation for each treatment option is shown in Table 6 . The majority of treatments were considered level U (no recommendation) on the basis of a paucity of high-quality and consistent evidence. No recommendation can be made for the following treatments: 1. Acetyl-L-carnitine (ALC) 2. Amitriptyline Table 2 . Level of confidence in evidence.
-High confidence corresponds to a "highly likely" conclusion; anchor is 2 Class I studies -Moderate confidence corresponds to "likely" conclusion; anchor is 1 Class I study or 2 Class II studies -Low Confidence corresponds to "possibly" conclusion; anchor is 1 Class II study, or 2 Class III studies -Very low confidence corresponds to "insufficient" conclusion; anchor is < 2 Class III Table 3 . Rating scheme for the strength of the recommendations.
Classification of recommendations
Level A Strongest recommendation, and is denoted by "must" or "must not"; based on high confidence in the evidence, and high magnitude of benefit and low risk; "must" recommendations are relatively rare Level B "Should" or "should not"; tend to be more common than A, since requirements are less stringent but still based on moderate evidence and risk/benefit profile Lamotrigine and topical KA (4% ketamine and 2% amitriptyline) should not be offered by physicians for treating CIPN, as they appear to have no benefit even in a large RCT study and many severe adverse events (AEs) in topical KA (35) .
To date, only Duloxetine and photobiomodulation (PBM) can be considered to provide a modest benefit for patients with CIPN. Physicians may offer them for patients with cancer experiencing CIPN. PBM, a low level laser therapy, showed significant improvement in modified total neuropathy score (mTNS) at 8 weeks. Although this was a high-quality study with consistent evidence, we downgraded to the low level of confidence in evidence (from moderate to low level) because the sample sizes appeared inadequate, and all the patients recruited were female. Therefore, we consider the evidence to show only modest symptom improvement with PBM for patients with CIPN at 8 weeks. www.painphysicianjournal.com between studies. However, we were able to develop recommendations for 4 of the examined modalities: clinicians may offer duloxetine or PBM, but they should not offer lamotrigine or topical KA. To improve the confidence in the results of clinical studies, 3 aspects of study design should be standardized: primary outcome measurement, chemotherapy regimens, and the timing of treatment entry.
Primary Outcome Measurements
A primary outcome measure was reported in 26 of the total 35 studies. Primary outcome measures included pain intensity by the Numeric Rating Scale (NRS), or Neuropathy Scale (ENS), Eastern Cooperative Oncology Group (ECOG) (18 studies), severity of neuropathy by NCI-CTCAE (4 studies), TNS or mTNS (4 studies), nerve conduction study (NCS) (4 studies), the Brief Pain Inventory (BPI) pain intensity (3 studies), the Neuropathic Pain Symptom Inventory (NPSI) (1 study), and the Pain Quality Assessment Scale (PQAS) (1 study), etc. No consensus exists regarding which of these measures are the best for assessing the outcomes of CIPN treatment. CIPN is a very common side effect of cancer treatment and cancer survivors present with sensory, motor and autonomic neuropathy. Clinically most patients with CIPN have sensory neuropathy, and among these patients, pain is one of the main complaint. However, some patients may have numbness, tingling, and gait imbalance as primary complaints. A few studies reported significant improvement in neuropathy but no change in pain intensity because the enrolled patients presented with mixed symptoms of neuropathy and not all patients had pain. This lack of standardized primary outcome measurements necessitates further studies that characterize and separate CIPN-related pain from other sensory symptoms; using standard outcome measures will help to determine the best outcome measure for www.painphysicianjournal.com (29) Insignificant in VAS before crossover (P = 0.78) but significant after crossover (p<0.04).
Significant increased hours of sleep in Nortrip (p<0.02) No significant differences in QOL, daily activity and preference of treatment between two arms. AEs: 6/51 discontinued due to AEs (2 from nortrip, 4 from PL). no major toxicity, but dry mouth, dizziness, and constipation are more common with nortrip. No significant change in LANSS, QST or objectively measured walking ability and hand dexterity.
Responders had a significantly greater degree of improvement than non-responders in PCS and dominant hand dexterity.
Class IV Very low
Level U Insufficient Small non RCT study. Mixed cancel related pain study, not specific study for CIPN. (CIPN is 61% of enrolled patients). As far as the severity of the neuropathy evaluation, there are several commonly used tools including NCI-CTCAE, TNS/mTNS, WHO toxicity grading, NCS/ EMG, the FACT/GOG-Ntx, EORTC-CIPN20 and PNQ. NCI-CTCAE is widely employed owing to its ease of use; it includes 2 items for use in clinical assessment of sensory and motor neuropathy, rated on a 0-4 grading scale. However, this tool is limited by its high rates of inter-observer disagreement and low sensitivity (8, 28, 53) . TNS has 7 items covering 7 domains, sensory, motor, autonomic symptoms, pin sensitivity, vibration sensitivity, strength, and tendon reflexes, whereas modified TNS (mTNS) does not include autonomic symptom. mTNS was the most highly rated clinical assessment tool in a recent Delphi survey, and enables assessment of both small and large nerve fiber function (54) . It is consistently reproducible and correlates with TNS, the gold standard of neuropathy assessment (33, 53, 55, 56) . The WHO toxicity grading scale, first published in 1979, developed a standardized approach to tumor treatment-related toxicity. The peripheral neuropathy section of this scale included measurements of paranesthesia, changes in deep tendon reflexes, and the extent of motor loss. However, it never became widely used for the assessment of CIPN (53) . NCS/EMG is painful, time consuming, and only detects large myelinated fibers of involved peripheral nerves. Because some chemotherapy drugs, for instance bortezomib, affects small myelinated and unmyelinated fibers, these tests are not ideal for assessing CIPN or for monitoring therapeutic response. The FACT/GOG-Ntx and the EORTC-CIPN20 scales have high sensitivity, are directly relevant to CIPN-related functional deficits, and are well correlated with objective measures of neuropathy (57) . FACT/GIG-Ntx contains 11 items divided into 5 sections: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns. EORTC-CIPN20 contains 20 items assessing sensory (9 items), motor (8 items), and autonomic symptoms (3 items), on a 0-4 grading scale. Even though FACT/GOG-Ntx and EORTC-CIPN20 appear to be the most comprehensive CIPN assessment tools, they are time consuming and of limited usefulness for primary outcome assessment. However, PNQ consists of only 3 items, rated on a 0-4 grading scale assessing sensory, motor, and function loss. The PNQ is www.painphysicianjournal.com convenient, and can be conducted without extensive equipment or training (54) .
Despite broad and viable tools of outcome measures for CIPN, further study should focus on a tool with high reliability and reproducibility across examiners to assess CIPN. Here we consider that FACT/GOG-Ntx andEORTC-CIPN20 are more appropriate for secondary outcome measurements, as they are more comprehensive than some other tools, involving assessments of function and quality of life. From among the currently available assessment tools, we support Cavaletti and colleagues' recommendation to use the TNS/mTNS and measurements of pain intensity by NRS as the primary outcome measurements, as these tools allow the most effective descriptions of the type and severity of CIPN (53) . In our review, 2 RCTs (25,33) with strong evidence adopted pain intensity and mTNS as primary outcome respectively.
Chemotherapeutic Agents
In order to better treat CIPN, a better understanding of the pathophysiological mechanisms of CIPN is needed. It is unclear why some agents that benefit diabetic peripheral neuropathic pain are not effective for treating CIPN (8, 10, 11) . Several mechanisms are involved in diabetic peripheral neuropathy; for example, diabetes mellitus causes changes in ion channel expression in peripheral nerve fibers, which in turn leads to hyperexcitability. Therefore, in patients with diabetic neuropathic pain, dysregulation of voltage-gated calcium channels leads to an enhanced calcium influx in sensory neurons (58) . The medications pregabalin and gabapentin are approved by the Food and Drug Administration for the first-line treatment of diabetic neuropathic pain because they selectively bind to presynaptic voltage-gated calcium channels in the brain and spinal cord, inhibiting of the release of excitatory neurotransmitters (59) (60) (61) . However, those medications are not effective in CIPN, suggesting the mechanisms of CIPN differ from those underlying other forms of peripheral neuropathy.
The mechanisms of CIPN also seem to depend upon the type of chemotherapeutic medication used. CIPN can by caused by antimicrotubule agents (taxanes, including paclitaxel and docetaxel), platinum compounds (cisplatin, carboplatin, oxaliplatin), proteasome inhibitors (bortezomib), immunomodulatory agents (thalidomide and lenalidomide) and vinca alkaloids (vincristine, vinblastine, and vinorelbine). Bortezomib causes a painful length dependent small fiber axonal sensory neuropathy by inhibiting proteasomes, the primary intracellular protein degradation machinery in neurons (62) . It also increases microtubule polymerization, and causes mitochondria to exhibit decreased axonal transport and function in sensory neurons (62) . Thalidomide is thought to cause peripheral neuropathy via both its immunomodulation and antiangiogenic effects, resulting in partially irreversible damage to distal axons and dorsal root ganglion (DRG) neurons from capillary damage and secondary anoxemia in nerve fibers (63, 64) . The platinum-based chemotherapeutics drugs work by forming interstrand DNA adducts, leading to cell cycle arrest, but this antineoplastic mechanism may also cause CIPN through damaging DRG by forming adducts with nuclear and mitochondrial DNA (65, 66) . In addition, oxaliplatin's effect on voltage-gated sodium channel kinetics causes cold-induced dysesthesia in the hands and mouth (67) . Taxane agents prevent microtubule depolymerization by binding to polymerized tubulin within microtubules in sensory neurons (68) . Vinca alkaloids, which are used for the primary treatment of hematological malignancies, predominantly cause sensory neuropathy, with some degree of motor involvement. In the contrast to the taxane agents, vinca alkaloids promote microtubule depolymerization by binding to microtubules, disrupting mitotic spindles and causing cell cycle arrest (68) . DRG sensory neurons, which are highly polarized, require proper microtubule function for axonal transport of mRNAs, proteins, mitochondria and other organelles. It helps to explain why these 2 drugs with opposite effects on microtubule stability both can cause CIPN (69, 70) . Although the mechanisms underlying CIPN are varied and unclear, most human and animal studies implicate axonal degeneration as a common process in CIPN pathology, which include defects in axon transport, altered mitochondrial function and altered calcium ion homeostasis (7) .
A large negative RCT of topical KA reported no significant improvement in pain, numbness, and tingling scores at 3 and 6 weeks (35) . However, the subgroup of patients who underwent taxane chemotherapy had significantly lower pain, numbness, and tingling scores than did patients in the non-taxane group at 6 weeks (35). These results suggest that topical KA may have benefits for patients whose CIPN is attributable to taxane agents. Given the varied mechanisms of chemotherapeutic agents, we consider that future study Treatment of Chemotherapy Induced Peripheral Neuropathy designs should focus on a single type of chemotherapeutic agent causing CIPN in order to better determine the efficacy of CIPN treatment. Table 4 outlines the timing of treatment entry for each study. Nineteen (54%) studies reported that CIPN treatment was initiated after completion of chemotherapy. Of those 19 studies, only 9 reported that the treatment started at least 3 months after completion of chemotherapy. In addition, 2 (6%) studies reported that the treatment started while patients were undergoing chemotherapy. Eight (23%) studies reported the timing of treatment occurred while patients had received and were receiving chemotherapy. Six (17%) studies were unclear on the timing of chemotherapy.
Timing of Treatment Entry
CIPN is fairly common within 1 month after cessation of chemotherapy, and its prevalence decreases over time. Approximately one-third of patients have chronic CIPN lasting 6 months or more after the end of chemotherapy (1) . The lack of uniformity in the timing of treatment entry among studies makes the results less convinced and also makes between-study comparisons difficult. In 2 large positive RCTs, the timing of treatment entry was at least 1 or 3 months, respectively, after completion of chemotherapy (25, 33) . Another 2 large negative RCTs reported that CIPN treatment started while patients had received and were receiving chemotherapy (9, 10) . These data suggest that the timing of treatment entry should be a standardized element of study design. We consider that at least 3 months after completion of chemotherapy is an appropriate timing of the treatment entry point, as this period would allow adequate time for self-recovery of involved peripheral nerves after cessation of chemotherapy.
Limitations
This review, while comprehensive, had some limitations. It included only literature published in English and the included studies were relatively poor homogeneous, with variations in timing of treatment, primary outcomes and chemotherapeutic agents used.
conclusions
These evidence-based clinical recommendations aimed to provide the best and most current evidence on the treatment of CIPN for physicians and patients. They have potential to improve the appropriateness and effectiveness of patient care by employing the best evidence available. In addition, these recommendations serve to identify knowledge, study design, and methodology gaps in the clinical literature on the treatment of CIPN. Future study should focus on using a standardized study design and outcome measures, large sample sizes and long-term follow-up for CIPN treatment trials.
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